866-997-4948(US-Canada Toll Free)

Opioid Tolerance Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Published By :

Transparency Market Research

Published Date : May 2019

Category :

Pharmaceutical

No. of Pages : 236 Pages

Global Opioid Tolerance Treatment Market: Overview

The global opioid tolerance treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug, type of opioid tolerance, route of administration, end-user, and region.

A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises a competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region, thereby presenting a thorough analysis of the overall competitive scenario in the global opioid tolerance treatment market.

Global Opioid Tolerance Treatment Market: Key Segments

  • The opioid tolerance treatment market has been categorized based on drug, type of opioid tolerance, route of administration, end-user, and region.
  • In terms of drug, the global market has been segregated into NMDA antagonists, alph2-adrenoceptor agonists, and others. The NMDA antagonists segment has been sub-segmented into ketamine, dextromethorphan, and others. Similarly, the alpha2-adrenoceptor agonists segment has been divided into clonidine, tizanidine, and others.
  • In terms of type of opioid tolerance, the global opioid tolerance treatment market has been bifurcated into innate tolerance and acquired tolerance.
  • Based on route of administration, the global market has been segmented into enteral, parenteral, and others.
  • In terms of end-user, the global opioid tolerance treatment market has been classified into hospitals & Ambulatory surgery centers, rehabilitation centers, and others.
  • Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The report provides current and future market size for each segment and sub-segments for the period from 2017 to 2027 in terms of revenue valued in US $ Mn, considering 2018 as the base year. The compound annual growth rate has been provided for each segment and market for the period of 2019 to 2027 with market size estimations. 

Global Opioid Tolerance Treatment Market: Regional Outlook

  • In terms of region, the global opioid tolerance treatment market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
  • These regions have been further sub-divided into major countries and sub-regions. Current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGR (%) for the period from 2019 to 2027. 

Companies Mentioned in Report

The global opioid tolerance treatment report concludes with the company profiles section that includes key information about the major players in the market. Key players identified in this report include

  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Otsuka Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services
  • Aurobindo Pharma
  • Pfizer Inc.
  • Acorda Therapeutics, Inc.
  • Zydus Cadila 

Each of these players have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. 

The global opioid tolerance treatment market has been segmented as follows: 

  • Global Opioid Tolerance Treatment Market, by Drug
  • NMDA Antagonists
  • Ketamine
  • Dextromethorphan
  • Others (including Guaifenisin)
  • Alpha2-adrenoceptor Agonists
  • Clonidine
  • Tizanidne
  • Others(including Lofexidine)
  • Others (including Endothelin Receptor Antagonists, NSAIDs, Opioid Combinations, and Multimodal Pain Management Drugs)
  • Global Opioid Tolerance Treatment Market, by Type of Opioid Tolerance
  • Innate Tolerance
  • Acquired Tolerance
  • Global Opioid Tolerance Treatment Market, by Route of Administration
  • Enteral
  • Parenteral
  • Others (including Transdermal Route, Patches, and Cartons of Patches) 
  • Global Opioid Tolerance Treatment Market, by End-user
  • Hospitals & ASCs
  • Rehabilitation Centers
  • Others (including Home Care Settings and Research Institutes) 
  • Global Opioid Tolerance Treatment Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of the Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Opioid Tolerance Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Opioid Tolerance Definition
4.1.2. Industry Evolutions / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Opioid Tolerance Treatment Market Analysis and Forecasts, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Key Mergers & Acquisitions 
5.2.Pipeline Analysis
5.3.Opioids Side Effects-an Overview
5.4.Overview of Opioid Tolerance and Epidemiology

6. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Drug 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug, 2017–2027
6.3.1. NMDA Antagonists
6.3.1.1. Ketamine
6.3.1.2. Dextromethorphan
6.3.1.3. Others
6.3.2. Alpha2-adrenoceptor Agonists
6.3.2.1. Clonidine
6.3.2.2. Tizanidine
6.3.2.3. Others
6.3.3. Others
6.4. Market Attractiveness by Drug 

7. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Type of Opioid Tolerance 
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
7.3.1. Innate Tolerance
7.3.2. Acquired Tolerance
7.4. Market Attractiveness, by Type of Opioid Tolerance 

8. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Route of Administration 
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2027
8.3.1. Enteral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness by Route of Administration 

9. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by End-user 
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2027
9.3.1. Hospitals 
9.3.2. Rehabilitation Centers
9.3.3. Others
9.4. Market Attractiveness by End-user 

10. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America 
10.2.2. Europe 
10.2.3. Asia Pacific 
10.2.4. Latin America 
10.2.5. Middle East & Africa 
10.3. Market Attractiveness by Country/Region

11. North America Opioid Tolerance Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug, 2017–2027
11.2.1. NMDA Antagonists
11.2.1.1. Ketamine
11.2.1.2. Dextromethorphan
11.2.1.3. Others
11.2.2. Alpha2-adrenoceptor Agonists
11.2.2.1. Clonidine
11.2.2.2. Tizanidine
11.2.2.3. Others
11.2.3. Others
11.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
11.3.1. Innate Tolerance
11.3.2. Acquired Tolerance
11.4. Market Value Forecast, by Route of Administration, 2017–2027
11.4.1. Enteral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2027
11.5.1. Hospitals 
11.5.2. Rehabilitation Centers
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2027
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis 
11.7.1. by Drug 
11.7.2. by Type of Opioid Tolerance 
11.7.3. by Route of Administration 
11.7.4. by End-user 
11.7.5. by Country/Sub-region

12. Europe Opioid Tolerance Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug, 2017–2027
12.2.1. NMDA Antagonists
12.2.1.1. Ketamine
12.2.1.2. Dextromethorphan
12.2.1.3. Others
12.2.2. Alpha2-adrenoceptor Agonists
12.2.2.1. Clonidine
12.2.2.2. Tizanidine
12.2.2.3. Others
12.2.3. Others
12.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
12.3.1. Innate Tolerance
12.3.2. Acquired Tolerance
12.4. Market Value Forecast, by Route of Administration, 2017–2027
12.4.1. Enteral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2027
12.5.1. Hospitals 
12.5.2. Rehabilitation Centers
12.5.3. Others
12.6.Market Value Forecast, by Country/Sub-region, 2017–2027
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis 
12.7.1. by Drug 
12.7.2. by Type of Opioid Tolerance 
12.7.3. by Route of Administration 
12.7.4. by End-user 
12.7.5. by Country/Sub-region

13. Asia Pacific Opioid Tolerance Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug, 2017–2027
13.2.1. NMDA Antagonists
13.2.1.1. Ketamine
13.2.1.2. Dextromethorphan
13.2.1.3. Others
13.2.2. Alpha2-adrenoceptor Agonists
13.2.2.1. Clonidine
13.2.2.2. Tizanidine
13.2.2.3. Others
13.2.3. Others
13.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
13.3.1. Innate Tolerance
13.3.2. Acquired Tolerance
13.4. Market Value Forecast, by Route of Administration, 2017–2027
13.4.1. Enteral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2027
13.5.1. Hospitals 
13.5.2. Rehabilitation Centers
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2027
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis 
13.7.1. by Drug 
13.7.2. by Type of Opioid Tolerance 
13.7.3. by Route of Administration 
13.7.4. by End-user 
13.7.5. by Country/Sub-region

14. Latin America Opioid Tolerance Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug, 2017–2027
14.2.1. NMDA Antagonists
14.2.1.1. Ketamine
14.2.1.2. Dextromethorphan
14.2.1.3. Others
14.2.2. Alpha2-adrenoceptor Agonists
14.2.2.1. Clonidine
14.2.2.2. Tizanidine
14.2.2.3. Others
14.2.3. Others
14.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
14.3.1. Innate Tolerance
14.3.2. Acquired Tolerance
14.4. Market Value Forecast, by Route of Administration, 2017–2027
14.4.1. Enteral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2027
14.5.1. Hospitals 
14.5.2. Rehabilitation Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2027
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis 
14.7.1. by Drug 
14.7.2. by Type of Opioid Tolerance 
14.7.3. by Route of Administration 
14.7.4. by End-user 
14.7.5. by Country/Sub-region

15. Middle East & Africa Opioid Tolerance Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug, 2017–2027
15.2.1. NMDA Antagonists
15.2.1.1. Ketamine
15.2.1.2. Dextromethorphan
15.2.1.3. Others
15.2.2. Alpha2-adrenoceptor Agonists
15.2.2.1. Clonidine
15.2.2.2. Tizanidine
15.2.2.3. Others
15.2.3. Others
15.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
15.3.1. Innate Tolerance
15.3.2. Acquired Tolerance
15.4. Market Value Forecast, by Route of Administration, 2017–2027
15.4.1. Enteral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2027
15.5.1. Hospitals 
15.5.2. Rehabilitation Centers
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2027
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis 
15.7.1. by Drug 
15.7.2. by Type of Opioid Tolerance 
15.7.3. by Route of Administration 
15.7.4. by End-user 
15.7.5. by Country/Sub-region

16. Competition Landscape
16.1. Market Player – Competition Matrix (by Tier and Size of companies)
16.2. Competitive Business Strategies
16.3. Company Profiles
16.3.1. Boehringer Ingelheim International GmbH
16.3.2. GlaxoSmithKline plc
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.4. Mylan N.V.
16.3.5. Otsuka Pharmaceutical Co., Ltd.
16.3.6. Johnson & Johnson Services, Inc.
16.3.7. Aurobindo Pharma
16.3.8. Pfizer Inc.
16.3.9. ACORDA THERAPEUTICS
16.3.10. Zydus Cadil

List of Table

List of Tables
Table 01: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 02: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
Table 03: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoreceptor Agonists), 2017–2027
Table 04: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
Table 05: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 06: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 07: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 10: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
Table 11: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoreceptor Agonists), 2017–2027
Table 12: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
Table 13: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 14: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 15: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 16: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 17: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
Table 18: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
Table 19: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
Table 20: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 21: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 22: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 24: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
Table 25: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
Table 26: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
Table 27: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 28: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 29: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 30: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 31: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
Table 32: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
Table 33: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
Table 34: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 35: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 36: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 37: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 38: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
Table 39: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
Table 40: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
Table 41: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
Table 42: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Chart

List of Figures 
Figure 01: Global Opioid Tolerance Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Revenue Share, by Drug
Figure 03: Revenue Share, by Type of Opioid Tolerance
Figure 04: Revenue Share, by Route of Administration
Figure 05: Revenue Share, by End-user
Figure 06: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 07: Global Opioid Tolerance Treatment Market Value Share, by Drug, 2018
Figure 08: Global Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018
Figure 09: Global Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018
Figure 10: Global Opioid Tolerance Treatment Market Value Share, by End-user, 2018
Figure 11: Global Opioid Tolerance Treatment Market Value Share, by Region, 2018
Figure 12: Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 13: Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
Figure 14: Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoreceptor Agonists), 2018 and 2027
Figure 15: Global Opioid Tolerance Treatment Market Revenue (US$ Mn), by NMDA Antagonists, 2017–2027
Figure 16: Global Opioid Tolerance Treatment Market Revenue (US$ Mn), by Alpha2-adrenoceptor Agonists, 2017–2027
Figure 17: Global Opioid Tolerance Treatment Market Revenue (US$ Mn), by Others, 2017–2027
Figure 18: Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Drug, 2017–2027
Figure 19: Global Opioid Tolerance Treatment Market Value Share Analysis, by Type of Opioid Tolerance, 2018 and 2027
Figure 20: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Innate Tolerance, 2017–2027
Figure 21: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Acquired Tolerance, 2017–2027
Figure 22: Opioid Tolerance Treatment Market Attractiveness Analysis, by Type of Opioid Tolerance, 2019–2027
Figure 23: Global Opioid Tolerance Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 24: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Enteral, 2017–2027
Figure 25: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2017–2027
Figure 26: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 27: Opioid Tolerance Treatment Market Attractiveness Analysis, by Route of Administration
Figure 28: Global Opioid Tolerance Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 29: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals & ASCs, 2017–2027
Figure 30: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Rehabilitation Centers, 2017–2027
Figure 31: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 32: Opioid Tolerance Treatment Market Attractiveness Analysis, by End-user
Figure 33: Global Opioid Tolerance Treatment Market Value Share, by Region, 2018 and 2027
Figure 34: Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 35: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 36: North America Opioid Tolerance Treatment Market Value Share, by Country, 2018 and 2027
Figure 37: North America Opioid Tolerance Treatment Market Attractiveness, by Country, 2019–2027
Figure 38: North America Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
Figure 39: North America Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
Figure 40: North America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
Figure 41: North America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
Figure 42: North America Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
Figure 43: North America Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
Figure 44: North America Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
Figure 45: North America Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 46: North America Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
Figure 47: North America Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
Figure 48: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 49: Europe Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 50: Europe Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 51: Europe Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
Figure 52: Europe Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
Figure 53: Europe Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
Figure 54: Europe Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
Figure 55: Europe Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
Figure 56: Europe Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
Figure 57: Europe Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
Figure 58: Europe Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 59: Europe Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
Figure 60: Europe Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
Figure 61: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 62: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 63: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 64: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
Figure 65: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
Figure 66: Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
Figure 67: Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
Figure 68: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
Figure 69: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
Figure 70: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
Figure 71: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 72: Asia Pacific Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
Figure 73: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
Figure 74: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 75: Latin America Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 76: Latin America Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 77: Latin America Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
Figure 78: Latin America Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
Figure 79: Latin America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
Figure 80: Latin America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
Figure 81: Latin America Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
Figure 82: Latin America Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
Figure 83: Latin America Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
Figure 84: Latin America Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 85: Latin America Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
Figure 86: Latin America Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
Figure 87: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 88: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 89: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 90: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
Figure 91: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
Figure 92: Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
Figure 93: Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
Figure 94: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
Figure 95: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
Figure 96: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
Figure 97: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
Figure 98: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
Figure 99: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *